Share

May 2018; 5 (3) ArticleOpen Access

Multicenter reliability of semiautomatic retinal layer segmentation using OCT

Timm Oberwahrenbrock, Ghislaine L. Traber, Sebastian Lukas, Iñigo Gabilondo, Rachel Nolan, Christopher Songster, Lisanne Balk, Axel Petzold, Friedemann Paul, Pablo Villoslada, Alexander U. Brandt, Ari J. Green, Sven Schippling
First published March 13, 2018, DOI: https://doi.org/10.1212/NXI.0000000000000449
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1200

Share

Article Information

vol. 5 no. 3 e449
DOI: 
https://doi.org/10.1212/NXI.0000000000000449
PubMed: 
29552598
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received October 3, 2017
  • Accepted in final form January 23, 2018
  • First Published March 13, 2018.
Copyright & Usage: 
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Timm Oberwahrenbrock, PhD*,
    2. Ghislaine L. Traber, MD*,
    3. Sebastian Lukas,
    4. Iñigo Gabilondo, MD,
    5. Rachel Nolan, BA,
    6. Christopher Songster,
    7. Lisanne Balk, PhD,
    8. Axel Petzold, MD,
    9. Friedemann Paul, MD,
    10. Pablo Villoslada, MD,
    11. Alexander U. Brandt, MD,
    12. Ari J. Green, MD** and
    13. Sven Schippling, MD**
  1. Timm Oberwahrenbrock, PhD*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) TEVA GmbH Germany, speaker honoraria (2) Bayer Germany, speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Federal Ministry of Education and Research (BMBF), EXISTS 03EFEB079, 2 years

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ghislaine L. Traber, MD*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Santhera; travel honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Sebastian Lukas,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Genzyme Bayer

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) Heidelberg Engineering GmbH CH, Application and Service Engineer, 1.5

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Iñigo Gabilondo, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Review Editor in Neuro-Ophthalmology, part of the journal(s) Frontiers in Neurology. Since 2nd May 2017.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Juan Rodes grant from Instituto de Salud Carlos III ?JR15/00008? (co- funded by European Regional Development Fund/ European Social Fund, ?Investing in your future?)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Rachel Nolan, BA,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Christopher Songster,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Lisanne Balk, PhD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. (1) Researcher in OCTIMS study, 5%, 3 years

    Research Support, Commercial Entities:

    1. (1) research support from TEVA

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Axel Petzold, MD,
    9. Scientific Advisory Boards:

    1. Advisory board on optical coherence tomography in MS (OCTiMS, CNF2333A2301), Novartis.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neuro-ophthalmology

    Patents:

    1. Listed as inventor on a patent on neurofilaments filed by the VUmc (P91964EP00 and P91964US00).

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Optical Coherence Tomography Quality Control Reading for Passos study (NCT01705236), Novartis.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. OCTiMS study (CNF2333A2301), Novartis.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. The research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Friedemann Paul, MD,
    10. Scientific Advisory Boards:

    1. Novartis OCTIMS study steering committee MedImmune steering committee

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire

    Editorial Boards:

    1. Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono

    Research Support, Government Entities:

    1. German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Pablo Villoslada, MD,
    11. Scientific Advisory Boards:

    1. Bionure

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neurology & Therapy, editorial board, 2014-2016 Curr There Op Neurol, editorial board 2014-2016 Mult Scl & Demyel Dis, editorial board 2015-- Systems Medicine 2017--

    Patents:

    1. 1. Methyltioadenosine for the treatment of MS 2. Agonistic neurotrophic compounds for the treatment of brain diseases 3. Gene signature pattern as a biomarker for MS 4. Algorithm for reconstructing white matter tracts from diffusion images

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Genentech

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. unrestricted grants from Novartis

    Research Support, Government Entities:

    1. Instituto de Salud Carlos III, European Commission, National MS Society, NIH

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Fundacion Maraton TV3, GAEM Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. Bionure Spire Bioventures Health Engineering Mint-Labs Roche

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. providing expert testimony for Synthon regarding patent issues with glatiramer acetate

  11. Alexander U. Brandt, MD,
    12. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) Pending patent Perceptive Visual Computing based Postural Control Analysis. (2) Pending patent Multiple Sclerosis Biomarker (3) Pending patent Perceptive Sleep Motion Analysis (4) Pending patent for fovea morphometry

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Motognosis

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1) Serves on the executive board of IMSVISUAL

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis Pharma (2) Biogen Idec

    Research Support, Government Entities:

    1. (1) BMWi, ZIM KF2443803KJ, PI, two years (2) BMWi, ZIM KF2291305AK3, Co-I, one year (3) BMWI, EXIST-FT 03EFEBE079, PI, two years (4) BMBF, NEU2 N2-ADVISIMS, Co-I, three years

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) The Guthy Jackson Charitable Foundation Stock/Stock Options, Medical Equipment & Materials: (1) Motognosis, 2014 (ongoing)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Ari J. Green, MD** and
    13. Scientific Advisory Boards:

    1. Medimmune End Point adjudication committee, Novartis Pharmaceuticals OCTIMS sterring committee, Inception 5 Biosciences Founder and Steering Committee, Bionure Scientfic Advisory Board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. JAMA Neurology Associate Editor Neurology Editorial Board December 2010-2015

    Patents:

    1. Remyelination molecules and pathways

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Inception 5 Sciences

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Novartis Pharma OCTIMs, Inception Sciences SRA

    Research Support, Government Entities:

    1. NINDS R01 NS088155-01 NIA 2R01AG038791-06A1

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National MS Society Sherak Foundation Hilton Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. Inception 5

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Mylan Pharmaceuticals v Teva Pharmaceuticals Expert Witness

  13. Sven Schippling, MD**
    14. Scientific Advisory Boards:

    1. 1.Bayer Healthcare 2.Biogen 3.Merck Serono 4.Novartis 5.Sanofi Genzyme 6.TEVA

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1.Bayer Healthcare, travel compensation, speaker honoraria 2.Biogen, travel compensation, speaker honoraria 3.Merck Serono, travel compensation, speaker honoraria 4.Sanofi Genzyme, travel compensation, speaker honoraria 5.TEVA, travel compensation, speaker honoraria

    Editorial Boards:

    1. Frontiers in Neurology, Associate Editor

    Patents:

    1. Therapeutic vaccination in PML using VP1 and IL7.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1. Sanofi Genzyme 2. Novartis

    Research Support, Government Entities:

    1. 1. University of Zurich, Clinical Research Priority Program, Co-Director, 3 years

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1. Betty and David Koetser Foundation for Brain Research 2. Swiss Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the NeuroCure Clinical Research Center (T.O., F.P., A.U.B.), Charité—Universitätsmedizin Berlin, Germany; Department of Ophthalmology (G.L.T.), University Hospital Zurich, University of Zurich; Neuroimmunology and Multiple Sclerosis Research Section (S.L., S.S.), Department of Neurology, University Hospital Zurich, University of Zurich, Switzerland; Center of Neuroimmunology (I.G., P.V.), Institut d'Investigacions Biomediques August Pi Sunyer (IDIBAPS)—Hospital Clinic, Barcelona, Spain; Division of Neuroinflammation and Glial Biology (R.N., C.S., A.J.G.), Department of Neurology, University of California San Francisco; Neuro-ophthalmology Division (A.J.G.), Department of Ophthalmology, University of California, San Francisco; Multiple Sclerosis Center (L.B., A.P.), Departments of Neurology and Ophthalmology, Neuro-ophthalmology Expertise Centre, VUmc, Amsterdam and Moorfields Eye Hospital (A.P.), The National Hospital for Neurology and Neurosurgery and UCL, United Kingdom; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité—Universitätsmedizin Berlin; Experimental and Clinical Research Center (F.P., A.U.B.), Charité—Universitätsmedizin Berlin and Max-Delbrück Center for Molecular Medicine, Germany; Department of Methods and Experimental Psychology (I.G.), Faculty of Psychology and Education, Universidad de Deusto, Bilbao, Spain.
  1. Correspondence
    Dr. Schippling sven.schippling{at}usz.ch
View Abstract

Article usage

Article usage: March 2018 to October 2023

AbstractFullPdfSource
Mar 2018427464Highwire
Apr 2018042625Highwire
Apr 2018112523pmc
May 2018045738Highwire
Jun 2018066518Highwire
Jun 2018101518pmc
Jul 201809912Highwire
Aug 201815012Highwire
Aug 201861515pmc
Sep 20180577Highwire
Oct 2018015010Highwire
Nov 201801156Highwire
Dec 2018017618Highwire
Jan 2019512110Highwire
Feb 201981226Highwire
Mar 2019115617Highwire
Apr 201942612Highwire
May 20199299Highwire
Jun 20196189Highwire
Jul 201942814Highwire
Aug 201937415Highwire
Sep 201973010Highwire
Oct 20193288Highwire
Nov 20194228Highwire
Dec 201982510Highwire
Jan 20202329Highwire
Feb 202042715Highwire
Mar 202031811Highwire
Apr 202061116Highwire
May 202033219Highwire
Jun 20207278Highwire
Jul 202031511Highwire
Aug 202072715Highwire
Sep 20201143029Highwire
Oct 202088716Highwire
Nov 2020132928Highwire
Dec 2020134325Highwire
Jan 2021123122Highwire
Feb 202163422Highwire
Mar 2021133618Highwire
Apr 2021112917Highwire
May 2021143521Highwire
Jun 20217408Highwire
Jul 202193821Highwire
Aug 2021103021Highwire
Sep 202193219Highwire
Oct 2021154040Highwire
Nov 202175341Highwire
Dec 2021175515Highwire
Jan 2022153514Highwire
Feb 202263412Highwire
Mar 2022164117Highwire
Apr 2022116717Highwire
May 2022137318Highwire
Jun 202285823Highwire
Jul 202261568Highwire
Aug 20221523111Highwire
Sep 20221114513Highwire
Oct 202295811Highwire
Nov 2022109134Highwire
Dec 2022123412Highwire
Jan 2023125722Highwire
Feb 2023114015Highwire
Mar 202392116Highwire
Apr 2023131513Highwire
May 2023152218Highwire
Jun 20234137Highwire
Jul 202362714Highwire
Aug 202342012Highwire
Sep 2023182018Highwire
Oct 2023132714Highwire

Letters: Rapid online correspondence

Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles